Erratum : Correction: MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2 (PLoS ONE (2015) 10(4): DOI:10.1371/journal.pone.0119783);MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Sun, Yang ^a   Zhang, Tingting ^a   Wang, Cuiping ^a   Jin, Xianglan ^a   Jia, Congwei ^a   Yu, Shuangni ^a   Chen, Jie ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 615 5P; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; AKT2 PROTEIN, HUMAN; MIRN615 MICRORNA, HUMAN; PROTEIN KINASE B;

3' UNTRANSLATED REGION; ADULT; AKT2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LOCKED NUCLEIC ACID IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN FUNCTION; RADIOIMMUNOPRECIPITATION; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL MOTION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

AGOUTI PACA; LENTIVIRUS;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84928796223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128257     Document Type: Erratum

References (49)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, v.1. Available: http://www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf. Accessed 2015 Feb 3.
2. Stathis A and Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010; 7: 163-172. doi: 10.1038/nrclinonc.2009.236 PMID: 20101258
3. Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996; 156: 2255-2260. PMID: 8885826
4. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L and Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000; 283: 2552-2558. PMID: 10815119
5. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ and Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001; 286: 921-929. PMID: 11509056
6. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996; 14: 141-145. PMID: 8841182
7. Jaffee EM, Hruban RH, Canto M and Kern SE. Focus on pancreas cancer. Cancer Cell. 2002; 2: 25-28. PMID: 12150822
8. Lohr M, Maisonneuve P and Lowenfels AB. K-Ras mutations and benign pancreatic disease. Int J Pancreatol. 2000; 27: 93-103. PMID: 10862508
9. Farrow B, Albo D and Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008; 149: 319-328. doi: 10.1016/j.jss.2007.12.757 PMID: 18639248
10. Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, et al. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain. 2005; 119: 233-246. PMID: 16298491
11. Lee RC, Feinbaum RL and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-854. PMID: 8252621
12. Zhao L, Chen X and Cao Y. New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai). 2011; 43: 831-839. doi: 10.1093/abbs/gmr080 PMID: 21908856
13. Hagan JP and Croce CM. MicroRNAs in carcinogenesis. Cytogenet Genome Res. 2007; 118: 252-259. PMID: 18000378
14. Liao WT, Li TT, Wang ZG, Wang SY, He MR, Ye YP, et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013; 19: 4662-4672. doi: 10.1158/1078-0432.CCR-13-0244 PMID: 23846336
15. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell. 2013; 24: 1638-1648, S1631-1637. doi: 10.1091/mbc.E12-12-0891 PMID: 23552692
16. Han Z, Yang Q, Liu B, Wu J, Li Y, Yang C, et al. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis. 2012; 33: 131-139. doi: 10.1093/carcin/bgr226 PMID: 22016468
17. Zhao G, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, et al. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKalpha1. Mol Cancer Ther. 2013; 12: 83-93. doi: 10.1158/1535-7163.MCT-12-0534-T PMID: 23171948
18. El Tayebi HM, Hosny KA, Esmat G, Breuhahn K and Abdelaziz AI. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett. 2012; 586: 3309-3316. doi: 10.1016/j.febslet.2012.06.054 PMID: 22819824
19. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem. 2002; 87: 470-476. PMID: 14735903
20. Ruggeri BA, Huang L, Wood M, Cheng JQ and Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998; 21: 81-86. PMID: 9496907
21. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996; 93: 3636-3641. PMID: 8622988
22. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004; 23: 8571-8580. PMID: 15467756
23. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004; 10: 2846-2850. PMID: 15102693
24. Koorstra JB, Hustinx SR, Offerhaus GJ and Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008; 8: 110-125. doi: 10.1159/000123838 PMID: 18382097
25. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010; 31: 1726-1733. doi: 10.1093/carcin/bgq160 PMID: 20675343
26. Yamamichi N, Shimomura R, Inada K, Sakurai K, Haraguchi T, Ozaki Y, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res. 2009; 15: 4009-4016. doi: 10.1158/1078-0432.CCR-08-3257 PMID: 19509156
27. Chehrehasa F, Meedeniya AC, Dwyer P, Abrahamsen G and Mackay-Sim A. EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J Neurosci Methods. 2009; 177: 122-130. doi: 10.1016/j.jneumeth.2008.10.006 PMID: 18996411
28. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010; 70: 6015-6025. doi: 10.1158/0008-5472. CAN-09-4531 PMID: 20610624
29. Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12: R81. doi: 10.1186/ar3006 PMID: 20459811
30. Lois C, Hong EJ, Pease S, Brown EJ and Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002; 295: 868-872. PMID: 11786607
31. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 18: 350-359. doi: 10.1038/cr.2008.24 PMID: 18270520
32. Ma Y, Yu S, Zhao W, Lu Z and Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010; 298: 150-158. doi: 10.1016/j. canlet.2010.06.012 PMID: 20638779
33. Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J Cell Sci. 1989; 92 (Pt 1): 123-130. PMID: 2674163
34. Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009; 37: D105-110. doi: 10.1093/nar/gkn851 PMID: 18996891
35. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838. PMID: 15944708
36. Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007; 26: 293-300. PMID: 17504025
37. Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, Statham AL, et al. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics. 2011; 12: 54. doi: 10.1186/1471-2164-12-54 PMID: 21255435
38. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2012; 18: 534-545. doi: 10.1158/1078-0432.CCR-11-0679 PMID: 22114136
39. Nelson PT and Wilfred BR. In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain. Neurosci Lett. 2009; 466: 69-72. doi: 10.1016/j. neulet.2009.04.044 PMID: 19393719
40. Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, et al. Fluorescencebased codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 2010; 16: 4246-4255. doi: 10.1158/1078-0432.CCR-10-1152 PMID: 20682703
41. Gray S, Pandha HS, Michael A, Middleton G and Morgan R. HOX genes in pancreatic development and cancer. JOP. 2011; 12: 216-219. PMID: 21546695
42. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol. 2010; 12: 235-246. doi: 10.1038/ncb2023 PMID: 20173741
43. Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M, et al. miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene. 2014; 0.
44. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20. PMID: 15652477
45. Bond-Smith G, Banga N, Hammond TM and Imber CJ. Pancreatic adenocarcinoma. BMJ. 2012; 344: e2476. doi: 10.1136/bmj.e2476 PMID: 22592847
46. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63: 318-348. doi: 10.3322/caac.21190 PMID: 23856911
47. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3: e3148. doi: 10.1371/journal.pone.0003148 PMID: 18773077
48. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297: 1901-1908. PMID: 17473300
49. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14: 1340-1348. doi: 10.1158/1078-0432.CCR-07-1755 PMID: 18316553